PainReform (NASDAQ:PRFX) vs. Vaxart (OTCMKTS:VXRT) Financial Comparison

PainReform (NASDAQ:PRFX) and Vaxart (OTCMKTS:VXRT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Profitability

This table compares PainReform and Vaxart’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Vaxart	15.88%	53.04%	20.85%

Volatility & Risk

PainReform has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Valuation & Earnings

This table compares PainReform and Vaxart”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20,000.00	32.19	-$5.02 million	($736.66)	-0.00
Vaxart	$237.26 million	0.42	$16.33 million	$0.16	2.56

Vaxart has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for PainReform and Vaxart, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
Vaxart	0	1	0	0	2.00

Institutional & Insider Ownership

37.3% of PainReform shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 2.8% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Vaxart beats PainReform on 8 of the 12 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.